Development and evaluation of solid lipid nanoparticles containing anti-migraine drug

Patil Satish K; Wagh Kalpesh S; Mali Kamlesh; Baviskar Dheeraj T; Jain Dinesh K

Authors

Patil Satish K Institute of Pharmaceutical Education, Boradi, Tal-Shirpur, Dist-Dhule, 425 428, India
Wagh Kalpesh S Institute of Pharmaceutical Education, Boradi, Tal-Shirpur, Dist-Dhule, 425 428, India
Mali Kamlesh Institute of Pharmaceutical Education, Boradi, Tal-Shirpur, Dist-Dhule, 425 428, India
Baviskar Dheeraj T Institute of Pharmaceutical Education, Boradi, Tal-Shirpur, Dist-Dhule, 425 428, India
Jain Dinesh K College of Pharmacy, I.P.S. Academy, Rajendra Nagar, Indore, 452 012, India

Keywords:

Naratriptan, Solid lipid Nanoparticles, migraine, hot high pressure homogenization

Abstract

The purpose of this research was to investigate novel particulate carrier system such as solid lipid nanoparticles for enhanced permeation of hydrophilic and lipophilic drug. A drug carrier of colloidal lipid particles with improved drug loading capacity and enhanced storage stability was investigated. A new type of solid lipid nanoparticles (SLN) has been developed by incorporating tripalmitine containing oils in the solid core of said particle. The hot high pressure homogenization technique was used as production methods for SLNs. The drug has poor bioavailability due to hepatic first-pass metabolism and low permeability into the brain due to efflux by P-glycoprotein’s, the present investigation aimed to prepare solid lipid nanoparticles by tripalmitine as lipid material, egg lecithin and Poloxamer 188 as emulsifying agent, Naratriptan is provide nose-to-brain delivery for brain targeting and sustained release. The drug-excipient study was performed by DSC and FTIR. The Solid Lipid Nanoparticles was evaluated and optimized for various parameters such as particle size, polydispersity index, zeta potential, encapsulation efficiency, in vitro drug release and stability studies were found to be 110±1.4nm, 0.22±0.02, –16.21±4.02, 95.20±0.1 and 98 % drug release respectively. SLNs formulation was subjected to stability study over a period of 3 month.